Location History:
- Yonkers, NY (US) (2004)
- Laurence Harbor, NJ (US) (2012)
- Lawrence Harbor, NJ (US) (2013 - 2015)
Company Filing History:
Years Active: 2004-2015
Title: Innovations by Florida Kallashi: A Contributor to Cardiovascular Drug Development
Introduction
Florida Kallashi, based in Lawrence Harbor, NJ, has made significant contributions to the field of pharmacology through his innovative inventions. With a total of four patents under his name, Kallashi focuses on developing compounds aimed at combating cardiovascular diseases, particularly those related to cholesterol management.
Latest Patents
His latest patents highlight two key inventions:
1. **Cyclic amine substituted oxazolidinone CETP inhibitor** - This invention features compounds that fall under Formula I, including pharmaceutically acceptable salts. These CETP inhibitors are specifically designed to raise HDL-cholesterol and reduce LDL-cholesterol, offering potential treatments for atherosclerosis. The compounds are structured with A as a substituted phenyl group or indanyl group.
2. **CETP inhibitors derived from benzoxazole arylamides** - In this patent, compounds are according to Formula I1, which are potent CETP inhibitors. They are valuable in raising HDL-cholesterol and reducing LDL-cholesterol as well, addressing the significant healthcare burdens associated with atherosclerosis and its related conditions such as coronary heart disease, stroke, and peripheral vascular disease. The structure of these compounds includes an arylamide moiety represented by A-B.
Career Highlights
Throughout his career, Florida Kallashi has worked with prominent companies in the pharmaceutical industry. He has been associated with Merck Sharp & Dohme Corporation and Merck & Company, Inc., where he contributed to various projects aimed at developing effective cardiovascular therapies.
Collaborations
Kallashi has collaborated with esteemed colleagues, including Julianne A. Hunt and Peter J. Sinclair. These partnerships have further enhanced the quality of research and innovations in the field of lipid management and cardiovascular health.
Conclusion
Florida Kallashi's contributions to the realm of CETP inhibitors and cardiovascular treatment reflect a dedicated effort to innovate and improve healthcare solutions. His patents not only address critical health issues but also signify the importance of collaboration and research in advancing medical science. With such a track record, Kallashi continues to be a vital figure in the pharmaceutical innovation landscape.